{"id":16463,"date":"2026-05-26T15:07:56","date_gmt":"2026-05-26T13:07:56","guid":{"rendered":"https:\/\/www.interpharma.ch\/?p=16463"},"modified":"2026-05-26T15:07:56","modified_gmt":"2026-05-26T13:07:56","slug":"3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/","title":{"rendered":"3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1575\" height=\"1181\" src=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited.jpg\" alt=\"Ein Bild von J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma\" class=\"wp-image-16474\" srcset=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited.jpg 1575w, https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited-800x600.jpg 800w, https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited-1200x900.jpg 1200w, https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited-768x576.jpg 768w, https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited-1536x1152.jpg 1536w\" sizes=\"auto, (max-width: 1575px) 100vw, 1575px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-you-b-ring-a-wealth-of-experience-from-various-countries-what-is-your-perspective-on-the-position-of-the-pharmaceutical-industry-in-switzerland\"><strong>You b<strong>ring a wealth of experience from various countries. What is your perspective on the position of the pharmaceutical industry in Switzerland?<\/strong><\/strong><\/h2>\n\n\n\n<p>Switzerland is rightly regarded as one of the world\u2019s leading life\u2011sciences hubs \u2014 the combination of scientific excellence, a strong innovation ecosystem, and a high\u2011quality healthcare system is unique. Coming from international markets, I see this reputation as well\u2011earned, but also increasingly under pressure.<\/p>\n\n\n\n<p>Patient access to innovative therapies has declined in recent years, with availability falling behind other comparable countries. Longer reimbursement timelines and a growing emphasis on short\u2011term cost containment make it harder for the system to keep pace with scientific progress. At the same time, global competition for investment and launch priority is intensifying, and new pricing dynamics are influencing where companies choose to bring innovation first.<\/p>\n\n\n\n<p>Switzerland is at an important inflection point. The decisions taken now \u2014 on access, predictability, and the overall attractiveness of the environment \u2014 will determine whether the country can maintain its leadership and ensure that patients continue to benefit from timely innovation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-w-here-do-you-see-switzerland-s-greatest-strengths-in-an-international-comparison\"><strong>W<strong>here do you see Switzerland\u2019s greatest strengths in an international comparison?<\/strong><\/strong><\/h2>\n\n\n\n<p>Switzerland\u2019s greatest strength is its uniquely integrated life\u2011sciences ecosystem. Few countries combine world\u2011class universities, leading healthcare institutions, and a highly innovative pharmaceutical and biotech industry in such a seamless and mutually reinforcing way. This creates an environment where scientific progress can move rapidly from discovery to real\u2011world impact.<\/p>\n\n\n\n<p>Internationally, Switzerland stands out for its consistent leadership in innovation metrics, including top positions in patents per capita in the life\u2011sciences sector. At the same time, the country benefits from a high\u2011performing healthcare system grounded in solidarity, broad access, and strong societal trust in science \u2014 an asset that cannot be taken for granted in many markets.<\/p>\n\n\n\n<p>This combination of scientific excellence, system performance, and societal trust makes Switzerland an exceptionally attractive location for research, development, and the delivery of high\u2011quality patient care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-s-a-newly-elected-member-of-the-interpharma-board-you-can-now-contribute-your-international-experience-to-the-swiss-pharmaceutical-industry-what-will-be-your-priorities\"><strong>A<strong>s a newly elected member of the Interpharma Board, you can now contribute your international experience to the Swiss pharmaceutical industry\u2014what will be your priorities?<\/strong><\/strong><\/h2>\n\n\n\n<p>My priority is to help ensure that Switzerland continues to be a leading life\u2011sciences hub while safeguarding timely access to innovative therapies for patients supported by a framework that appropriately rewards scientific innovation. These two goals are inseparable: a strong innovative ecosystem only delivers its full value when patients can benefit from new treatments without unnecessary delay.<\/p>\n\n\n\n<p>To achieve this, we need stable and predictable framework conditions that support long\u2011term investment, encourage scientific progress, and maintain Switzerland\u2019s global competitiveness. This requires close collaboration between policymakers, the healthcare system, and industry to develop sustainable, forward\u2011looking solutions rather than short\u2011term fixes.<\/p>\n\n\n\n<p>In this context, I see my role as combining determination with partnership \u2014 setting clear ambitions for the future while working constructively with all stakeholders to deliver them.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma<\/p>\n","protected":false},"author":8,"featured_media":16464,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[114,119,129,181],"class_list":["post-16463","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-research","tag-innovation-en","tag-pharmastandort-2030-en","tag-patientenzugang"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb\" \/>\n<meta property=\"og:description\" content=\"J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T13:07:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1575\" \/>\n\t<meta property=\"og:image:height\" content=\"2362\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"georgdaerendinger\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"georgdaerendinger\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/\"},\"author\":{\"name\":\"georgdaerendinger\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/084d5698c6a33caa3c77f9b64b2e4359\"},\"headline\":\"3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb\",\"datePublished\":\"2026-05-26T13:07:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/\"},\"wordCount\":501,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg\",\"keywords\":[\"Research\",\"Innovation\",\"Pharmastandort 2030\",\"Patientenzugang\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/\",\"url\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/\",\"name\":\"3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg\",\"datePublished\":\"2026-05-26T13:07:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg\",\"width\":1575,\"height\":2362,\"caption\":\"Ein Bild von J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/084d5698c6a33caa3c77f9b64b2e4359\",\"name\":\"georgdaerendinger\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g\",\"caption\":\"georgdaerendinger\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/","og_locale":"en_US","og_type":"article","og_title":"3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb","og_description":"J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma","og_url":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/","og_site_name":"Interpharma","article_published_time":"2026-05-26T13:07:56+00:00","og_image":[{"width":1575,"height":2362,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg","type":"image\/jpeg"}],"author":"georgdaerendinger","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"Written by":"georgdaerendinger","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/"},"author":{"name":"georgdaerendinger","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/084d5698c6a33caa3c77f9b64b2e4359"},"headline":"3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb","datePublished":"2026-05-26T13:07:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/"},"wordCount":501,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg","keywords":["Research","Innovation","Pharmastandort 2030","Patientenzugang"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/","url":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/","name":"3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg","datePublished":"2026-05-26T13:07:56+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg","width":1575,"height":2362,"caption":"Ein Bild von J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma"},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/en\/blog\/3-questions-to-our-new-board-member-jerome-garcin-general-manager-for-switzerland-and-austria-bei-bristol-myers-squibb\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/en\/"},{"@type":"ListItem","position":2,"name":"3 questions to our new board member: J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/084d5698c6a33caa3c77f9b64b2e4359","name":"georgdaerendinger","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g","caption":"georgdaerendinger"}}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/posts\/16463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/comments?post=16463"}],"version-history":[{"count":8,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/posts\/16463\/revisions"}],"predecessor-version":[{"id":16522,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/posts\/16463\/revisions\/16522"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/media\/16464"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/media?parent=16463"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/tags?post=16463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}